Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Unlike software startups that need revenue growth, deep tech and hard tech companies (e.g., building nuclear reactors) can secure large Series A rounds by demonstrating progress against scientific or engineering milestones. This marks a return to milestone-based funding for capital-intensive ventures.

Related Insights

The venture capital benchmark for a successful Series A fundraising round has dramatically shifted from 3x to 10x year-over-year growth. This new standard is driven by AI's ability to accelerate company scaling and heightened market expectations.

The established SaaS growth playbook, where achieving milestones like $1M to $4M in ARR guaranteed follow-on funding, is no longer relevant. Hyper-growth AI companies have dramatically raised the bar for what is considered 'venture fundable,' forcing SaaS founders to consider alternative financing or reaching profitability much earlier.

For projects requiring hundreds of millions, fundraising should be split into phases. The initial "pre-industrialization" phase, focused on proving technology, is suited for venture capital. Later phases for manufacturing and scaling should target project finance structures with debt/equity combinations and strategic partners.

When traditional metrics like ARR or DAUs are unavailable, ambitious hard-tech startups can leverage large, non-binding Letters of Intent (LOIs) from future customers to validate their vision and attract early-stage investment.

OpenAI is labeling its massive $100B+ funding round a "Series C," a term typically for much smaller raises. This highlights the unprecedented capital requirements of building foundational AI models, effectively creating a new category of venture financing that dwarfs traditional funding stages and signals a new era for capital-intensive startups.

Unlike SaaS, deep tech companies have a unique valuation trajectory: a sharp seed-to-Series A increase, a long plateau during R&D, and then massive step-ups post-production. This requires a bimodal investment strategy focusing on early stage and the final private round before inflection.

Companies tackling moonshots like autonomous vehicles (Waymo) or AGI (OpenAI) face a decade or more of massive capital burn before reaching profitability. Success depends as much on financial engineering to maintain capital flow as it does on technological breakthroughs.

For deep tech startups lacking traditional revenue metrics, the fundraising pitch should frame the market as inevitable if the technology works. This shifts the investor's bet from market validation to the team's ability to execute on a clear technical challenge, a more comfortable risk for specialized investors.

Unlike traditional software, AI model companies can convert capital directly into a better product via compute. This creates a rapid fundraising-to-growth cycle, where money produces a superior model with a small team, generating immediate demand and fueling the next, larger round.

Companies with long-term, capital-intensive goals and no immediate path to profitability are being valued like biotech firms. Both public and private markets are willing to fund these "moonshots" for years before revenue materializes, a model familiar in drug development but novel for mainstream tech.

Deep Tech Startups Can Now Raise Series A Rounds on Milestones, Not Revenue | RiffOn